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Abstract
Intervertebral disc (IVD) degeneration is a frequent disease in modern societies and at its later stages is likely to cause chronic
low back pain. Although many studies have been published, the available treatments for IVD degeneration fail to promote
regeneration or even marginal repair of the IVD structure. In this study, we aimed to establish veterinary canine patients as a
translational large animal model that recapitulates IVD degeneration that occurs in humans, and to investigate the suitability of
intradiscal application of mesenchymal stromal cells (MSC). Twenty client-owned dogs diagnosed with spontaneous degen-
erative lumbosacral IVD and low back pain were included in the study. Autologous MSC were isolated from bone marrow and
cultured for 2 weeks. Prior to injection, MSC were attached on collagen microcarriers for delivery, with or without TGF-b1
crosslinking. After decompressive spinal surgery, dogs received an intradiscal injection of MSC-microcarriers (n ¼ 11), MSC-
TGF-b1-microcarriers (n¼ 6) or microcarriers only (control, n¼ 3). MSC-microcarriers were initially evaluated in vitro and ex
vivo, to test cell chondrogenic potential and biomechanical properties of the microcarriers, respectively. Clinical performance
and Pfirrmann grading were evaluated at 10 months after the injection by magnetic resonance imaging. MSC differentiated
successfully in vitro towards chondrogenic phenotype and biomechanical tests showed no significant differences of IVD stiffness
after microcarrier injection. In vivo injection was successful in all dogs, without any visible leakage, and clinical functioning was
restored back to normality. However, postoperative Pfirrmann grade remained identical in all dogs, and formation of
Schmorl’s nodes was detected in 45% of dogs. This side effect was reduced by halving the injection volume, which was then
observed only in 11% of dogs. In conclusion, we observed marked clinical improvement in all groups, despite the formation of
Schmorl’s nodes, but microcarriers and MSC failed to regenerate the structure of degenerated IVD.
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Introduction
Low back pain caused by intervertebral disc (IVD) degen-
eration1 is one of the most common contemporary medical
problems in people2,3. Despite improved diagnostic and ther-
apeutic options, including advanced diagnostic imaging
techniques and numerous conservative and surgical treat-
ment procedures, these measures remain ineffective in a
certain percentage of affected people. Since IVD degenera-
tion is incurable, all available treatment strategies are mainly
focused on pain relief only, while the underlying aetiology
remains unaddressed. Therefore, progression of segmental
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disease due to ongoing disc degeneration has stimulated a
large interest in developing strategies with the potential to
regenerate – or at least repair and preserve the functioning of
the IVD structure. Among these, intradiscal injection of
mesenchymal stromal cells (MSC) has become highly topi-
cal in experimental and clinical investigations4.
The advantages of using MSC include their availability
from various adult tissues – such as bone marrow and adi-
pose tissue5,6 – their multilineage potential7 and their bene-
ficial immunomodulatory properties and ability to reduce
local inflammation8. Although in vitro studies demonstrated
that MSC transplanted into degenerated IVD maintained
viability, proliferation and differentiation9, the translation
of these positive results into a clinical setting is challenging
for various reasons. On the analytical side, evidence for IVD
regeneration can only be obtained histologically by demon-
strating increased numbers of disc chondrocytes and increase
of proteoglycan content. Because it is unethical to obtain
intact disc tissue from living human patients, magnetic reso-
nance imaging (MRI) is the only available technique. MRI
can detect only changes of disc hydration as a signal in the
nucleus pulposus, which is an indirect measure associated to
proteoglycan content and, ultimately, changes in disc size
(which fluctuates diurnally). A more intense signal of the
nucleus pulposus in T2-weighted MRI images after MSC
transplantation is regarded to be equivalent to increased
synthesis of proteoglycans by disc chondrocytes. MRI inves-
tigations of disc regeneration have yielded conflicting
results. On the one hand, in small laboratory animals and
experimental dogs with artificially induced disc degenera-
tion, there was an increase in signal paralleled by prolifera-
tion of disc chondrocytes and reversal of histological signs of
degeneration10. On the other hand, in clinical studies, visible
effects for regeneration evidenced by increased fluid signal
seen by MRI were only present in a small percentage of
cases in people and absent in the only canine study11,12.
Nevertheless, the use of dogs for veterinary clinical stud-
ies presents several advantages: (i) The procedure we
applied in veterinary patients would replicate closely the
standard in human clinical trial conditions. (ii) Dogs
involved in the study naturally developed IVD degeneration
and the typical associated pain, establishing a strong link to
human complaints. (iii) The size of the dogs included in the
study – comparable to humans – prevented any issue of
scaling up, which might occur with experimental models like
rodents. (iv) Finally, the methods of evaluation – functional
score and MRI appearance – are very similar to those used in
human medicine. For these four reasons, a canine clinical
model of IVD degeneration was selected as a translational
approach for testing the suitability of autologous MSC-
based, IVD-injection therapy.
Recently, we published our results from a pilot clinical
study investigating a therapy with autologous bone marrow-
derived MSC in the absence of extracellular matrix carrier in
dogs with spontaneous IVD degeneration, in which we could
not find MRI proof for improvement of disc morphology12.
We further hypothesized that the difficult environment –
under constant load, hypoxic conditions13 and limited room
to divide – might lead to an absence of visible disc regenera-
tion. To address these problems, we designed collagen
microcarriers based on a medical device approved for human
use as a support to deliver MSC into the disc. This scaffold
provides mechanical strength and can be used to immobilize
growth factors14 – such as transforming growth factor-b1
(TGF-b1) – in order to keep them locally at a sufficient
concentration, thus promoting the desired differentiation
conditions. Additionally, microcarriers have the advantage
of being injectable and thus are uncomplicated to deliver into
a patient’s discs during surgery.
The purpose of the present translational clinical investi-
gation was three-fold. First, to assess in vitro the suitability
of microcarriers to support chondrogenic differentiation of
canine MSC; second, to investigate ex vivo the injectability,
biomechanical strength and leakage behaviour of collagen-
based microcarriers using canine lumbosacral segments
dissected from Beagle dogs; and third, to test the safety and
effectiveness in clinically affected dogs – measured by an
improved Pfirrmann score – of intradiscal injection of
MSC-microcarrier, with or without TGF-b1 crosslinking,
into spontaneously degenerated lumbosacral IVD. Dogs
were followed prospectively using a clinical scoring system
and MRI.
Materials and Methods
Mechanical Testing on Isolated Cadaveric
Lumbosacral Segments
Leftover material from an unrelated study was used for this
testing in order to minimize the use of experimental ani-
mals. Lumbosacral segments from six healthy and young
adult Beagle dogs were used for biomechanical testing. The
dogs were bred for experimental use and served as controls
in a pharmacological study (Novartis Pharma AG, Basel,
Switzerland). After euthanasia and necropsy the lumbosa-
cral joint (L6-S2) was isolated from the cadavers and freed
from muscles leaving the ligamentous structures intact. The
spinal specimens were then donated to our institution and
stored at 20C.
After thawing, the proximal and distal ends of the spinal
specimens were embedded in polymethylmethacrylate
(PMMA) for uniform transmission of the loading forces
(Fig. 2A). The prepared spinal specimens were mounted
on a testing machine (Instron Electropulse E 10000) and
exposed to cyclic loading. For testing, the distal vertebral
body/PMMA was fixed to the Instron base plate, while the
top pot with the embedded proximal vertebral body could
move freely (Fig. 2A). For each test, the samples were
loaded 5600 times in combined compression and bending
by applying 20–200 N axial compression through a pin offset
25 mm from the centre vertical axis of the specimen and
machine actuator. The loading frequency was 2 Hz and the
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data were acquired at 10 Hz. The loading protocol was
defined that 100 loading steps were applied on each of the
four positions of the pin (the actuator and pin were rotated
90 sequentially to anterior–right–posterior–left), and this
was repeated for 14 loading cycles. Therefore, 14 (full load-
ing cycles)  4 (positions)  100 (loading steps) ¼ 5600
loading steps in total were applied. Each specimen was
tested sequentially three times, (1) in the intact condition,
(2) after 72 h of the nucleus pulposus digestion injected with
a papain solution (120 U/mL, Sigma, Buchs, Switzerland)
and (3) after injection of 0.5 ml microcarrier solution (250
mg collagen/5 mL phosphate-buffered saline solution (PBS),
AppliChem, Axonlab, Baden, Switzerland) - previously
stained with coomassie blue (AppliChem) - into the digested
nucleus pulposus through the ventral annulus. In total, 18
tests were performed and evaluated. To determine whether
there was leakage of the microcarriers during the loading
procedure, the specimens were filmed (time lapse, one pic-
ture every two seconds) and visually observed. After the
loading procedure, the lumbosacral disc was cut in a trans-
verse plane and the cut surfaces were examined for presence
of stained microcarrier solution.
Clinical Study
Study population. Twenty client-owned dogs were recruited
from consecutive appointments at the neurological service of
the clinic for small animals, Vetsuisse faculty of the Univer-
sity of Zurich. Dogs were included in the study when clinical
signs and MRI findings confirmed the diagnosis of degen-
erative lumbosacral stenosis (DLSS) caused by a degener-
ated and centrally protruded L7-S1 disc. Only dogs
diagnosed with overt compression of the cauda equina nerve
roots by a protruded and degenerated IVD were selected.
Breeds included: Belgian Malinois, Labrador Retriever, Ger-
man Shepherd, Berger Blanc Suisse, Rhodesian Ridgeback,
German Longhair and Dalmatian. Fourteen dogs were male,
six dogs were female, and the median weight was 34.5 kg
(range 25–42 kg) with a median age of 6 years (range 3–8
years old). Written owner consent was obtained for all ani-
mals. Since the dogs included in this study were clinical
patients with a clear indication for decompressive surgery
and not experimental animals, intradiscal injection of MSC-
microcarrier could be performed concomitantly without any
additional invasive procedures. All dogs presented with a
Fig. 1. In vitro assessment of chondrogenic potential of canine MSC. MSC (n ¼ 4) were seeded on microcarriers crosslinked by RB/UV with
0, 100 or 400 ng/mL TGFb1, or not crosslinked (controls), and cultured for 28 days. (A) Starting from a suspension, at the end of the assay
MSC-microcarriers fused together to form a single and small construct. (B) The total amount of cells per sample was similar between groups,
however the accumulation of glycosaminoglycan (C) was significantly higher in presence of TGFb1, both crosslinked or in suspension.
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complaint of chronic history of back pain suggestive of a
lesion in the lumbosacral area. A standardized owner ques-
tionnaire was used to collect historical details. All dogs were
examined by a board-certified veterinary neurologist and
subjected to a standardized clinical examination. Clinical
signs of back pain for all dogs included caudal lumbar pain
that manifested as difficulties jumping and occasional crying
during exercise. Pain could be elicited when pressure was
applied to the lumbosacral junction and during the lordosis
test of the caudal lumbar spine in all dogs. The results of the
clinical assessment and owner questionnaire were combined
and expressed in a custom-designed score to quantify the
dogs’ clinical status. A dog without lumbosacral pain and
normal neurological function of the cauda equina received a
score of 21. Diagnosis of DLSS was confirmed by MRI
demonstrating compression of the nerve roots of the cauda
equina due to protrusion of a degenerated lumbosacral disc.
MSC isolation, culture and cell-microcarrier preparation. Autolo-
gous bone marrow-derived MSCwere harvested and isolated
from clinically affected dogs, as published previously12,15.
Briefly, bone marrow was obtained under general anaesthe-
sia from the iliac crest. Bone marrow samples were diluted in
3.8% sodium citrate (AppliChem) to prevent clotting. After
addition of PBS, samples were centrifuged at 500g for 10
minutes. The isolated cells (including erythrocytes) were
counted and plated at a density of 5  107 cells/cm2 in a-
MEM (Amimed – Bio Concept, Allschwil, Switzerland) sup-
plemented with 10% foetal bovine serum (FBS), 100 units/
mL penicillin/streptomycin (both Gibco – LuBioScience,
Lucerne, Switzerland) and 2.5 mg/mL amphotericin B
(AppliChem) at 37C, 5% CO2 and 5% O2. After 2 days,
non-adherent cells were removed, while adherent cells were
washed with PBS and then cultured as described above,
except medium was supplemented with 5 ng/mL human
recombinant basic fibroblast growth factor (bFGF, Pepro-
tech – LuBioScience).
After 8–10 days – depending on how fast cells were
growing – MSC were detached, counted and seeded at a
density of 3  106 cells/250 mg on collagen microcarriers
(MSC-microcarrier)16, with or without crosslinking with 100
ng/mL of human recombinant TGF-b1 (Peprotech) by ribo-
flavin (RB) (AppliChem) and UV radiation (MSC-TGF-b1-
microcarriers)14. Briefly, the preparation of microcarriers
was achieved by shearing of a sterile collagen sponge pad
soaked in PBS in Dispomix Drive system (Axonlab). Then,
microcarriers were incubated for 2 h at 37C in 160 mM RB
solution, followed by 250 mJ/sec UVA irradiation for 5 min
into a UV crosslinker (Stratalinker – Stratagene, Basel, Swit-
zerland), and three washes in PBS. TGF-b1 was covalently
bound to activated microcarriers for 2 h at room temperature,
followed by quenching with 50 mM glycine (AppliChem)
and three washes in PBS. Finally, cell attachment to scaf-
folds was promoted by incubating cell suspension with
microcarriers in non-adherent propylene tubes (Falcon).
MSC-microcarrier and MSC-TGF-b1-microcarriers were
left to settle 2 days in a hypoxic culture medium at 37C,
5% CO2 and 5%O2. Before injection, both preparations were
washed with PBS. The whole protocol, from bone marrow
sampling to cell-microcarriers injection, lasted between 12
to 14 days.
MSC transplantation. Clinically affected dogs underwent a
decompressive surgical procedure consisting of a dorsal
laminectomy of the most caudal aspect of L7 and S1. After
gentle retraction of the cauda equine nerve roots, the under-
lying dorsal annulus fibrosus was exposed and the injection
site of MSC-microcarrier suspension could be easily identi-
fied. The procedure has been published in detail
previously12.
Dogs were randomly assigned to groups receiving an
injection consisting of a suspension of MSC and microcar-
riers (group 1; n ¼ 11), MSC and microcarriers crosslinked
with TGF-b1 (group 2; n ¼ 6) and microcarriers only (con-
trol group; n ¼ 3) in PBS. Initially, 1 mL of the suspension
was injected into degenerated IVD (group 1), but the volume
was reduced to 0.5 mL (group 2 and control group) after
interim analysis of follow-up MRI, to prevent the potential
formation of Schmorl’s nodes. The suspension was injected
into the L7/S1 IVD, at a depth of 1 cm into the centre
(nucleus pulposus), using a 0.7 mm needle (22G) and a 2
ml syringe. After injection, the vertebral canal was flushed
with physiologic saline and the wound was closed in a rou-
tine manner.
Post-operative care consisted of administration of parent-
eral buprenorphine (0.02 mg/kg iv; Temgesic, Reckitt
Benckiser AG) for the first 24 h, and carprofen (4 mg/kg
post-operatively; Canidryl, Dr. E. Gra¨ub AG) for 6 days.
Post-operative exercise consisted of short walks of 5 min
three times daily during the first week, followed by increased
exercise on the leash in a stepwise manner over 4 weeks.
After this initial period of restricted activity, dogs were gra-
dually familiarized to unlimited activity for a further 4
weeks.
Follow-up – clinical status, owner assessment and diagnostic
imaging for evaluation of regenerative effects. Dogs were exam-
ined 1 day after surgery and 10 months post-operatively, as
described previously by our group12. Briefly, clinical assess-
ment consisted of a physical and neurological examination
performed by a board-certified neurologist (FS) to identify
neurological deficits and signs of pain. For the late follow-
up, the standardized owner questionnaire was again used to
evaluate the dogs’ condition during unrestricted, daily exer-
cise. If dogs developed clinical signs before the 10 months
follow-up, they were assessed and scored clinically and
underwent an intermediate MRI examination.
MRI of the lumbosacral junction was performed to sup-
port the clinical diagnosis of DLSS and to assess the degen-
erative stage of the IVD using the Pfirrmann scheme
validated for dogs17, prior to and after treatment. A 3 T MRI
system (Philips Ingenia 3 T with dStream body coil solution;
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Philips AG) was used. Dogs were positioned in dorsal
recumbence with the pelvic limbs in extension. T2-
weighted and T1-weighted turbo spin echo sequences were
obtained.
In-Vitro Testing of Canine MSC on
Crosslinked Microcarriers
Preparation of crosslinked microcarriers was performed as
already described in our previous work16. Briefly, microcar-
riers were incubated for 2 h at 37C in 160 mM RB solution
(AppliChem), followed by 250 mJ/sec UV-A irradiation for
5 min into a UV crosslinker (Stratalinker). TGF-b1 (Pepro-
tech) was covalently bound to activated microcarriers for 2 h
at room temperature in a final volume of 500 mL, and then
quenched with 50 mM glycine (AppliChem). Crosslinked
microcarriers were used as a support for chondrogenic dif-
ferentiation. Cell attachment to scaffolds was promoted by
incubating cell suspension with microcarriers in non-
adherent propylene tubes (Falcon; Faust, Schaffhausen,
Switzerland).
Chondrogenic culture. To induce chondrogenesis, microcar-
riers were cross-linked with 0, 100 ng/ml and 400 ng/mL
TGF-b1 before cell attachment. 5 mg of cross-linked micro-
carriers and 3 x 105 canine MSC (n¼ 4) were cultured for 28
days under hypoxic conditions (5% O2), in medium consist-
ing of DMEM/Ham’s F12 (Gibco), supplemented with 2.5%
FBS, 40 ng/mL dexamethasone (AppliChem), 50 mg/mL
ascorbate-2-phosphate (Sigma), 50 mg/mL L-proline
(Sigma), 100 U/mL penicillin/streptomycin, 2.5 mg/ml
amphotericin B and 1X ITS-X supplement (10 mg/ml Insulin,
5.5 mg/ml Transferrin and 0.67 ng/ml Selenium; Gibco). As
controls, non-cross-linked MSC-microcarriers were differ-
entiated in absence (negative) or presence (positive) of 10
ng/ml TGF-b1 in culture medium. All media were changed
three times per week.
Cell counting. At the end on the differentiation assay, MSC-
microcarriers were digested with 0.3% pronase (Invitrogen)
and 0.05% collagenase type II (Gibco) in DMEM/Ham’s
F12, supplemented with 10% FBS, 100 U/mL penicillin/
streptomycin and 2.5 mg/ml Amphotericin B at 37C for 2
h. After washing with PBS, cells were counted using trypan
blue dye in Neubauer chamber (Bioswisstec, Schaffhausen,
Switzerland).
Glycosaminoglycan (GAG) quantification. GAG accumulation
was quantified with alcian blue binding assay after 6 h diges-
tion of three constructs per sample at 60C with 125 mg/ml
papain (Sigma) in 5 mM L-cysteine-HCl (Fluka-Sigma), 5
mM Na-citrate, 150 mM NaCl, 5 mM EDTA (all Appli-
Chem). GAG accumulation was determined by binding to
alcian blue (Sigma), absorption was measured at 595 nm and
quantified against chondroitin sulphate (Sigma) reference
standards18. Total double stranded DNA was measured for
each sample after papain digestion. The amount of DNA was
determined using SYBR green (Invitrogen) fluorescent assay
(absorption measured at 535 nm), quantified by referring to
calf thymus DNA standards (Sigma).
Statistical Analysis
Differences in mechanical behaviour of IVD ex vivo were
assessed by Kruskal–Wallis test, while changes in cell
counts and GAG accumulation was analysed by non-
parametric Mann–Whitney–Wilcoxon U test for dependent
variables. For all tests, p < 0.05 was considered significant.
Data analysis was performed with SPSS 25.0 for Windows
(SPSS Inc., Chicago, IL, USA).
Results
Chondrogenic Differentiation In Vitro of Canine MSC
on TGF-b1 Crosslinked Microcarriers
Prior to MSC seeding, microcarriers were crosslinked with 0,
100 and 400 ng/mL TGF-b1 by RB/UV (MSC-TGF-b1-
microcarriers). As controls, MSC were seeded on microcar-
riers not crosslinked and cultured with (positive control) or
without (negative control) 10 ng/mL TGF-b1 in solution.
Starting with an initial loose consistency at day 1, MSC-
TGF-b1-microcarriers (n ¼ 4) fused together and formed,
after 28 days in culture, a single solid spherical construct per
well in all groups (Fig. 1A). Compared to controls, MSC-
TGF-b1-microcarriers showed no significant variations in
the number of cells retained per sample; on average 1.06 x
105 cells/sample (Fig. 1B). GAG accumulation was quanti-
fied by alcian blue precipitation reaction (Fig. 1C) and in the
absence of TGF-b1, cells accumulated almost 50% less
GAG (7 mg GAG/mg DNA) compared to positive control
(14 mg GAG/mg DNA; p < 0.05). The crosslinked MSC-
TGF-b1 group promoted similar to the positive control pro-
teoglycan accumulation (16 mg GAG/mg DNA).
Biomechanical Testing on Isolated Cadaveric
Lumbosacral Segments
Before IVD loading tests (Fig. 2A), some samples showed
stiffness and alignment changes after digestion of the
nucleus pulpous (Fig. 2B). The injection of microcarriers
into the digested IVD led to a restoration of disc height and
orientation. During IVD loading, every test was filmed in
time lapse and visually evaluated. The tests showed that in
all cases (n¼ 6) the injected microcarriers were not expelled
during loading. After loading tests, IVD were transversely
sectioned, and retention of pre-stained with coomassie blue
microcarriers in situ was observed in all specimens (Fig. 2C).
To have an objective measure of possible mechanical
changes due to digestion and microcarrier injection, a stiff-
ness analysis was performed. Stiffness evaluation per load-
ing step was defined as the maximum gradient in the linear
region of the force-displacement curve. Since every sample
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was loaded on four positions (anterior–right–posterior–left)
and the test consisted of multiple loading cycles over time, a
mean stiffness for each position and each loading cycle was
calculated. The stiffness values for all the positions were
compared within the three conditions (non-digested,
digested, digested with microcarriers). It was expected that
the non-digested and the digested samples would show dif-
ferent stiffness parameters and that with the injection of the
collagen microcarriers into the digested discs the stiffness
would tend to go back to non-digested state. Some of the
samples showed a minor tendency towards such behaviour,
but these improvements were not statistically significant
(data not shown).
Feasibility, Safety and Clinical Outcome
Dogs treated with microcarriers improved in terms of pain
and disability score (Table 1). The median pre-operative
score of dogs treated with MSC-microcarriers (n ¼ 11) was
14.0 (range 12–19) and improved to a median final post-
operative score of 20 (range 20–21). Dogs injected with
MSC-TGF-b1-microcarrries (n ¼ 6), had a median pre-
operative score of 16.0 (range 13–16) and a post-operative
score of 20.5 (range 20–21). In the group of dogs treated with
microcarriers only (n ¼ 3), the pre-operative score was 14.0
(range 11–16) and the score improved to 21 (range 20–21) at
the end of the study. When mean values of postoperative
improvement were compared, they were 6 and 7 score points
respectively for the MSC-microcarriers treated dogs and the
microcarriers-only treated dogs. After 10 months, follow-up
MRI showed no changes of the Pfirrmann score of degener-
ated IVD injected with MSC-microcarriers (Fig. 3A), MSC-
TGF-b1-microcarriers (Fig. 3B) and microcarriers only (Fig.
3C). Therefore, pre- and post-operative score in all dogs
were identical (Table 2).
Although intradiscal injections were well-tolerated clini-
cally by 18 dogs, 2 dogs developed clinical signs consisting
of increased pain in the lower back, reluctance to rise and
move and occasional vocalization during exercise during the
follow-up period. Clinical signs occurred 3–4 months after
intradiscal injection of an MSC-microcarrier. In both dogs,
the neurological examination revealed a short-stridden gait
Fig. 2. Ex vivo stiffness evaluation of canine IVD, before and after microcarrier injection. (A) The procedure used to test IVD stiffness is
summarized in the diagram. Preceding loading test, nucleus pulposus was digested with papain (injected laterally into the disc) for 72 hours.
(B) Following digestion, the upper part of IVD segment was inclined due to heterogeneous structural impairment of the disc, and injection of
microcarriers restored the alignment. The IVD segment was then fixed to the Instron machine and loaded 5600 times (20 N to 200 N) with
the loading point offset 25 mm from the centre axis. (C) After injection of the microcarrier (stained with coomassie blue) and the loading
procedure, no microcarriers were visually extruded and the transversal cut of the IVD shows blue areas indicating retainment of the injected
microcarriers.
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in the pelvic limbs, an abnormal posture with flexion of the
caudal lumbar area and the tail was carried in low position.
Painful reactions could be elicited during palpation of the
lumbosacral area and lordosis. Neurological deficits were
not detected in any of the dogs and the physical examination
and blood haematology and chemistry did not reveal any
abnormalities. Both dogs underwent an intermediate MRI
examination to investigate the source of the clinical problem.
MRI showed specific morphological abnormalities/lesions
absent on pre-operative images (Fig. 4A). Specifically, the
lesions were characterized by focal and rounded hyperinten-
sities in the subchondral marrow on T2-weighted images of
Table 1. Pre- and Post-Operative Clinical Scores of the Dogs Suffering Degenerative Lumbosacral Stenosis.
Dog breed
Pre-operative
score
Intermediate
post-operative score*
Final post-operative
score
MSC þ microcarriers German Shepherd 15 – 21
German Shepherd 18 – 21
Berger Blanc Suisse 14 – 21
Border Collie 15 – 21
Labrador Retriever 14 12 19
Belgian Malinois 15 – 21
Belgian Malinois 12 – 21
Labrador Retriever 15 17 20
Belgian Malinois 14 – 21
Dalmatian 11 – 21
German Shepherd 19 – 21
MSC þ TGFb1 crosslinked microcarriers German Shepherd 16 – 21
German Shepherd 13 – 20
Rhod. Ridgeback 16 – 21
German Longhair 16 – 20
German Shepherd 14 – 21
German Shepherd 16 – 20
Microcarriers only Labrador Retriever 14 – 21
Belgian Malinois 16 – 21
German Shepherd 11 – 20
*Intermediate post-operative scoring was performed only in dogs that developed clinical signs during the follow-up period.
Fig. 3. Magnetic resonance imaging of pre- and post-operative IVD. Sagittal T2-weighted MRI of spontaneously degenerated lumbosacral
discs treated with MSC þ microcarriers (n ¼ 11), MSC þ TGFb1 crosslinked microcarriers (n ¼ 6) and microcarriers only (n ¼ 3, control
group). Injection into L7/S1 was performed ventrally, and microcarriers were injected at both side of IVD to obtain a more uniform spread
into the nucleus pulposus. After 10 months, MRI follow-up showed neither improvement nor deterioration of the IVD morphology.
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L7 and S1 (Fig. 4B). T1-weighted images (Fig. 4C) revealed
defects in the endplates at the level of the previously
described hyperintensities approximatively at the level of
the nucleus pulposus. After administration of intravenous
contrast medium (Fig. 4D), there was marked enhancement
in the area of the hyperintensities and endplate defects. No
contrast accumulation was observed within the IVD or para-
vertebral structures (Fig. 4). Morphology and signal changes
of the lesions fulfilled the diagnostic criteria for Schmorl’s
nodes (SN) – nucleus pulposus protrusion into vertebral
body – as described in people and dogs19,20. Six dogs
(30%) developed SN: five dogs injected with MSC-
microcarriers (1 mL injection volume), and one dog with
MSC-TGF-b1-microcarriers and microcarriers only (0.5
mL injection volume). We observed that the reduction of
injection volume from 1 mL to 0.5 mL decreased the risk
of SN formation (from 45% to 11%). Four of six dogs
affected with SN did not display clinical signs and only two
dogs described above had transient lumbosacral pain.
The two dogs with lumbosacral pain were treated with
non-steroidal anti-inflammatory drugs (Carprofen 4mg/kg
orally every 24 hours) and antibiotics (Clavaseptin 12.5 mg/
kg orally every 12 hours for 14 days; Vetoquinol AG) and
were returned to limited exercise and rest. Following these
measures, a return to normal function was observed within 10
days. After a follow-up at 10 months, the dogs were without
lumbosacral pain and had clinical scores comparable to those
of the unaffected dogs (20 for both). Interestingly, SN forma-
tion was associated with an increased Pfirrmann score at the
time of the final MRI only in one affected dog.
Discussion
The present investigation demonstrated that MSC seeded on
collagen microcarriers can be easily administered and the
constructs remain in situ after intradiscal injection in canine
lumbosacral discs. However, MRI showed no signs of disc
regeneration based upon the Pfirrmann grade, meaning that
the degeneration status of the IVD did not improve after 10
months post-operative in any of the three groups. Concomi-
tantly, we did not observe any progression of IVD degenera-
tion by stab of the thin needle (0.7 mm–1.0 mm int./ext.
diameter) through which the microcarriers were injected.
Recently, we published a study in which dogs suffering
IVD degeneration were treated with autologous bone
marrow-derived MSC in absence of injectable scaffold, in
which similarly, we were not able to demonstrate any appar-
ent regenerative effect of the treatment. In fact, progression
of degeneration (1 Pfirrmann grade) was observed in dogs
receiving MSC whereas in dogs with only saline injection,
the Pfirrmann grade remained the same 12 months post
injection12. There are various causes for the modest effec-
tiveness of disc regeneration in the naturally degenerated
disc. Once injected into the IVD, MSC will face the chal-
lenges of a difficult environment, under constant load and
hypoxic conditions13. Additionally, after removal of degen-
erated disc tissue, the implanted cells may need too much
time to differentiate and generate new disc tissue and a more
probable scenario might be that undesired scar tissue (col-
lagen type-I) is formed instead21, or cells which leaked out of
the disc and reached bone surfaces form osteophytes22. To
Table 2. Evaluation of Pre- and Post-Operative Degree of Degeneration of L7-S1 Intervertebral Discs in the Treated Dogs, Based on the
Pfirrmann Grading Scale.
Dog breed
Pre-operative
degree
Intermediate
post-operative degree*
Final post-operative
degree
MSC þ microcarriers German Shepherd 3 – 3
German Shepherd 3 – 3
Berger Blanc Suisse 3 – 3
Border Collie 3 – 3
Labrador Retriever 3 3 SN 4 SN
Belgian Malinois 3 – 3 SN
Belgian Malinois 4 – 4 SN
Labrador Retriever 3 3 SN 3 SN
Belgian Malinois 3 – 3 SN
Dalmatian 3 – 3
German Shepherd 3 – 3
MSC þ TGFb1 crosslinked microcarriers German Shepherd 3 – 3
German Shepherd 4 – 4
Rhod. Ridgeback 3 – 3
German Longhair 4 – 4 SN
German Shepherd 2 – 2
German Shepherd 3 – 3
Microcarriers only Labrador Retriever 3 – 3
Belgian Malinois 3 – 3
German Shepherd 3 – 3
*Intermediate post-operative scoring was performed only in dogs that developed clinical signs during the follow-up period; SN ¼ Schmorl’s nodes.
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address these problems, we pre-cultured MSC in hypoxic
conditions (5% O2) and transferred them on collagen micro-
carriers in the role of three-dimensional (3D) scaffolds, to
improve cell viability and accelerate the process of matrix
production after intradiscal injection. Additionally, we used
microcarriers crosslinked with immobilized TGF-b1 in order
to keep the growth factor at high local concentration14, thus
hoping to recreate improved cell differentiation conditions,
as we could prove in vitro. However, despite clinical
improvement of the treated dogs after the injection of
MSC-TGF-b1-microcarriers, there was no MRI-detectable
improvement of IVD morphology reflected by the Pfirrmann
score.
Marked clinical improvement was noted in all groups,
suggesting that improved function was rather due to the
concomitant surgical decompression than being related to
intradiscal cell therapy. However, these results cannot be
translated directly into the human situation because func-
tional differences between groups may become obvious in
people due to improvements in pain that can only be
obtained by verbal communication as used in the Oswestry
disability index, which includes more thorough testing pro-
cedures and verbal communication allowing a more precise
grading than was possible in animals. Lack of precise
description of pain sensation and disability represent the
main problems when animal models are used for transla-
tional comparative studies.
From a biomechanical point of view, we evaluated the
apparent disc stiffness throughout the ex vivo testing and
registered the mechanical changes. As expected from a vis-
coelastic material, every IVD showed certain creep beha-
viour. Creeping in the IVD occurs partly due to
viscoelastic effects, but primarily by water expulsion from
the tissue. Creep was observed in all specimens. However,
no consistent differences were found between the groups.
The evaluation of the apparent stiffness did not show signif-
icant differences between the three groups (non-digested
IVD, digested IVD and microcarriers þ digested IVD), for
any of the loading cycles evaluated (i.e. short- or long-term).
From a morphological point of view, microcarriers can serve
as a scaffold for repopulation of local IVD cells and also as a
spacer, but with no demonstrable mechanical advantage.
In the ex vivo experiment, no leakage was observed dur-
ing mechanical loading after injection of stained microcar-
riers. Leakage, that is, extrusion of injected MSC through the
puncture site of the dorsal annulus fibrosus, has been asso-
ciated with both lack of regeneration of the IVD and adverse
side-effects. A previous study reported that less than 1% of
labelled MSC were detected in the nucleus pulposus after
injection of MSC in saline23. In addition, extruded MSC
have been associated with osteophyte-formation at the punc-
ture site representing a potentially painful complication22.
Consequently, prevention of cell leakage was a main focus
of our study and other groups’ investigation. A recent experi-
mental study in rabbit discs demonstrated that MSC in col-
lagen microspheric microcarriers resulted in a reduced risk
for osteophyte formation at the puncture site because they
remained in situ24. Based upon these experimental results,
newly designed clinical trials were expected to outperform
Fig. 4. Morphology and signal changes occurring with Schmorl’s
nodes formation. Pre-operative T2-weighted MRI (A) and different
sequences of an intermediate post-operative MRI study (B-D) of
the lumbosacral area of a six-year-old Labrador Retriever that
developed clinical signs three months after injection of MSC þ
microcarrier into L7-S1. T2-weighted MRI (B) with diffuse hyper-
intense signal in the area of nucleus pulposus, adjacent endplate and
subchondral bone marrow. T1-weighted MRI (C) demonstrating
focal defects in the endplates of L7 and S1. Gadolinium enhanced
T1-weighted MRI (D) with marked contrast uptake within the sub-
chondral bone marrow at the level of the endplate defects. There is
also a small area of contrast uptake in the dorsal annulus indicating a
fissure in the degenerated annulus fibrosus and ingrowth of vessels
(white arrow).
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the modest results of previous clinical trials in people and
dogs using MSC suspension in saline injected into the IVD.
However, our clinical investigation demonstrated that
prevention of extrusion did not enhance disc regeneration
based upon assessment of improved Pfirrmann grade and
moreover, bears the risk of a previously undescribed side
effect consisting of the formation of Schmorl’s nodes
(SN). SN are protrusions of disc material into the vertebral
body and contact the subchondral bone marrow where it
induces inflammation. This is the first evidence of this pre-
viously undescribed, undesired side effect in intradiscal cell
therapies. Focal failure of endplate is a key element in the
pathophysiology of SN. Various pathologies involving the
spine may weaken the IVD and vertebral endplates, allowing
SN to form. Specifically, trauma, IVD degeneration, conge-
nital abnormalities and autoimmune mechanisms were iden-
tified as aetiologies25. In the present study, the association
between SN and intradiscal injection of MSC-microcarriers
was straightforward. The most likely hypothesis is that SN
resulted from increased focal pressure on the endplate by the
microcarrier deposit. Clinically, SN are often incidental
findings and remain clinically silent in people (14). As only
two of six dogs with SN were clinically affected in the pres-
ent study, this seems to apply also to veterinary patients. We
could reduce the occurrence of SN from 45% to 11% of the
cases, by decreasing the injection volume of from 1 mL to
0.5 mL. As a direct consequence we recommend using lower
injection volumes in IVD cellular therapy, especially when
scaffolds are used.
As limitations of the study, we could not introduce any
segmental stabilization of the lumbosacral vertebra – in addi-
tion to microcarrier injection – to neutralize biomechanics
because this would have changed the study. Furthermore,
due to the restricted number of dogs, we could not test more
than one cell concentration (3  106 MSC/dog) per IVD
treated. Assignment of dogs to the different groups was per-
formed in a consecutive way, that is, the first group was
treated with MSC-microcarriers, followed by the second
group with MSC-TGF-b1-microcarriers. Since the interim
analysis of the follow-up MRI revealed no improvement of
the Pfirrmann grade in the group treated with MSC-
microcarriers, we opted to stop the recruitment, resulting
in an uneven distribution of dogs per group. In addition, the
relatively low number of clinical cases precluded the use of
inferential statistics which may have affected some of the
results of this investigation. In the small microcarriers-only
group one of the dogs started with a very low clinical score
of 11 due to incontinence and improved with nine score
points, reaching the average for all groups end score of 20,
potentially introducing an outlier bias.
In conclusion, injection of MSC seeded on microcarriers
into IVD prevented leakage of MSC but did not regenerate
the canine lumbosacral IVD. Formation of SN was an unde-
sired side effect of this treatment protocol; however, the
clinical outcome was not affected by this complication.
Partially, the risk of this complication can be reduced by
lowering the injection volume.
Ethical Approval
Injection of MSC into the dogs’ IVD was performed concomitantly
with the clinically indicated surgical decompression in all cases and
ethical approval was not needed for this article.
Statement of Human and Animal Rights
Leftover lumbosacral segments from six healthy and young adult
Beagle dogs were used for biomechanical testing (the dogs were
bred for experimental use and served as controls in another, phar-
macological, study by Novartis Pharma AG, Basel, Switzerland).
The lumbosacral joint (L6-S2) was isolated from the cadavers and
freed from muscles leaving the ligamentous structures intact. The
spinal specimens were then donated to our institution and stored
at 20C.
Since the dogs included in this clinical study were not experi-
mental animals but considered clinical patients with a clear
indication for decompressive surgery, intradiscal injection of
MSC-microcarrier could be performed concomitantly without any
additional invasive procedures.
Statement of Informed Consent
Written informed consent was obtained from the owners of the
patient dogs.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect
to the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support
for the research, authorship, and/or publication of this article: This
research was supported by the Swiss Paraplegic Foundation and the
Swiss National Foundation (Grant number: CR2313_159744).
ORCID iD
Jivko Stoyanov https://orcid.org/0000-0001-6842-6284
References
1. Luoma K, Riihimaki H, Luukkonen R, Raininko R, Viikari-
Juntura E, Lamminen A. Low back pain in relation to lumbar
disc degeneration. Spine (Phila Pa 1976). 2000;25(4):487–92.
2. Wieser S, Horisberger B, Schmidhauser S, Eisenring C, Brug-
ger U, Ruckstuhl A, Dietrich J, Mannion AF, Elfering A, Tam-
can O, et al. Cost of low back pain in Switzerland in 2005. Eur J
Health Econ. 2011;12(5):455–67.
3. Wenig CM, Schmidt CO, Kohlmann T, Schweikert B. Costs of
back pain in Germany. Eur J Pain. 2009;13(3):280–6.
4. Zeckser J, Wolff M, Tucker J, Goodwin J. Multipotent
mesenchymal stem cell treatment for discogenic low back pain
and disc degeneration. Stem Cells Int. 2016;2016:3908389.
5. Kisiel AH, McDuffee LA, Masaoud E, Bailey TR, Esparza
Gonzalez BP, Nino-Fong R. Isolation, characterization, and
in vitro proliferation of canine mesenchymal stem cells derived
from bone marrow, adipose tissue, muscle, and periosteum.
Am J Vet Res. 2012;73(8):1305–17.
210 Cell Transplantation 28(2)
6. Ryu HH, Kang BJ, Park SS, Kim Y, Sung GJ, Woo HM, Kim
WH, Kweon OK. Comparison of mesenchymal stem cells
derived from fat, bone marrow, Wharton’s jelly, and umbilical
cord blood for treating spinal cord injuries in dogs. J Vet Med
Sci. 2012;74(12):1617–30.
7. Kang BJ, Ryu HH, Park SS, Koyama Y, Kikuchi M, Woo HM,
Kim WH, Kweon OK. Comparing the osteogenic potential of
canine mesenchymal stem cells derived from adipose tissues,
bone marrow, umbilical cord blood, and Wharton’s jelly for
treating bone defects. J Vet Sci. 2012;13(3):299–310.
8. Vela DC, Silva GV, Assad JA, Sousa AL, Coulter S, Fernandes
MR, Perin EC, Willerson JT, Buja LM. Histopathological
study of healing after allogenic mesenchymal stem cell deliv-
ery in myocardial infarction in dogs. J Histochem Cytochem.
2009;57(2):167–76.
9. Le Maitre CL, Baird P, Freemont AJ, Hoyland JA. An in vitro
study investigating the survival and phenotype of mesenchy-
mal stem cells following injection into nucleus pulposus tissue.
Arthritis Res Ther. 2009;11(1):R20.
10. Hiyama A, Mochida J, Iwashina T, Omi H, Watanabe T, Ser-
igano K, Tamura F, Sakai D. Transplantation of mesenchymal
stem cells in a canine disc degeneration model. J Orthop Res.
2008;26(5):589–600.
11. Orozco L, Soler R, Morera C, Alberca M, Sanchez A, Garcia-
Sancho J. Intervertebral disc repair by autologous mesenchy-
mal bone marrow cells: a pilot study. Transplantation. 2011;
92(7):822–8.
12. Steffen F, Smolders L, Roentgen A, Bertolo A, Stoyanov J.
Bone marrow-derived mesenchymal stem cells as autologous
therapy in dogs with naturally occurring intervertebral disc
disease: Feasibility, safety and preliminary results. Tissue Eng
Part C Methods. 2017;23(11):643–51.
13. AdamsMA,Roughley PJ.What is intervertebral disc degeneration,
and what causes it? Spine (Phila Pa 1976). 2006;31(18):2151–61.
14. Bertolo A, Arcolino F, Capossela S, Taddei AR, Baur M, Pot-
zel T, Stoyanov J. Growth factors cross-linked to collagen
microcarriers promote expansion and chondrogenic differen-
tiation of human mesenchymal stem cells. Tissue Eng Part A.
2015;21(19-20):2618–28.
15. Bertolo A, Steffen F, Malonzo-Marty C, Stoyanov J. Canine
mesenchymal stem cell potential and the importance of dog
breed - implication for cell-based therapies. Cell Transplant.
2014;24(10):1969–80.
16. Bertolo A, Hafner S, Taddei AR, Baur M, Potzel T, Steffen F,
Stoyanov J. Injectable microcarriers as human mesenchymal
stem cell support and their application for cartilage and degen-
erated intervertebral disc repair. Eur Cell Mater. 2015;29:
70–81.
17. Bergknut N, Auriemma E, Wijsman S, Voorhout G, Hagman
R, Lagerstedt AS, Hazewinkel HA, Meij BP. Evaluation of
intervertebral disk degeneration in chondrodystrophic and non-
chondrodystrophic dogs by use of Pfirrmann grading of images
obtained with low-field magnetic resonance imaging. Am J Vet
Res. 2011;72(7):893–8.
18. Bjornsson S. Simultaneous preparation and quantitation of pro-
teoglycans by precipitation with alcian blue. Anal Biochem.
1993;210(2):282–91.
19. Gendron K, Doherr MG, Gavin P, Lang J. Magnetic resonance
imaging characterization of vertebral endplate changes in the
dog. Vet Radiol Ultrasound. 2012;53(1):50–6.
20. Mattei TA, Rehman AA. Schmorl’s nodes: current pathophy-
siological, diagnostic, and therapeutic paradigms. Neurosurg
Rev. 2014;37(1):39–46.
21. Raj PP.Intervertebral disc: Anatomy-physiology-pathophysiol-
ogy-treatment. Pain Pract. 2008;8(1):18–44.
22. Vadala G, Sowa G, Hubert M, Gilbertson LG, Denaro V, Kang
JD. Mesenchymal stem cells injection in degenerated interver-
tebral disc: cell leakage may induce osteophyte formation. J
Tissue Eng Regen Med. 2012;6(5):348–55.
23. Crevensten G, Walsh AJ, Ananthakrishnan D, Page P,
Wahba GM, Lotz JC, Berven S. Intervertebral disc cell
therapy for regeneration: mesenchymal stem cell implanta-
tion in rat intervertebral discs. Ann Biomed Eng. 2004;
32(3):430–4.
24. Li YY, Diao HJ, Chik TK, Chow CT, An XM, Leung V,
Cheung KM, Chan BP. Delivering mesenchymal stem cells
in collagen microsphere carriers to rabbit degenerative disc:
reduced risk of osteophyte formation. Tissue Eng Part A. 2014;
20(9-10):1379–91.
25. Kyere KA, Than KD, Wang AC, Rahman SU, Valdivia-Valdi-
via JM, La Marca F, Park P. Schmorl’s nodes. Eur Spine J.
2012;21(11):2115–21.
Steffen et al 211
